Results 61 to 70 of about 88,754 (289)

Targeting the Membrane‐Embedded Rhomboid Protease GlpG: A Multimodal Strategy for Inhibitor Discovery and Mechanistic Insight

Angewandte Chemie, EarlyView.
Created in BioRender. Bohg, C. (2026) https://BioRender.Com/ vi9hi4f. Rhomboid proteases are a mechanistically unique and evolutionarily conserved protein family. Despite their pharmacological relevance, the development of selective inhibitors has lagged behind that of soluble proteases.
Claudia Bohg, Yurii Dubanych, Spyridon Kosteletos, Taoran Xiao, Martin Neuenschwander, Tillmann Utesch, Michael Lisurek, Carl Öster, Andreas Oder, Carola Seyffarth, Kathrin Bach, Denise‐Liù Gracias Leone, František Filandr, Marc Wegert, Sascha Lange, Henry Sawczyc, Jens Peter von Kries, Christian P. R. Hackenberger, Edgar Specker, Han Sun, Kvido Stříšovský, Adam Lange   +21 more
wiley   +2 more sources

Systemic and Intra-Habenular Activation of the Orphan G Protein-Coupled Receptor GPR139 Decreases Compulsive-Like Alcohol Drinking and Hyperalgesia in Alcohol-Dependent Rats. [PDF]

, 2018
GPR139 is an orphan G protein-coupled receptor (GPCR) that is expressed mainly in the brain, with the highest expression in the medial habenula. The modulation of GPR139 receptor function has been hypothesized to be beneficial in the treatment of some ...
Conlisk, Dana, de Guglielmo, Giordano, George, Olivier, Kallupi, Marsida, Kimbrough, Adam, Kononoff, Jenni   +5 more
core  

Prediction and classification for GPCR sequences based on ligand specific features [PDF]

, 2006
Functional identification of G-Protein Coupled Receptors (GPCRs) is one of the current focus areas of pharmaceutical research. Although thousands of GPCR sequences are known, many of them are orphan sequences (the activating ligand is unknown). Therefore,
F. Horn, G.E. Tusnády, K.R. Sreekumar, M. Bouvier, R. Karchin, S. Altshul, T. Gudermann, W. Pearson, Y. Huang   +8 more
core   +1 more source

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020

Orphanet Journal of Rare Diseases, 2011
Background Orphan drugs are a growing issue of importance to European healthcare policy makers. The success of orphan drug legislation in Europe has resulted in an increasing number of licensed medicines for rare diseases, and many more yet unlicensed ...
Milanova Tsveta, Schey Carina, Hutchings Adam   +2 more
doaj   +1 more source

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China

罕见病研究, 2023
Rare diseases are characterized by extremely low incidence rate and small number of patients in total. The drugs used to treat rare diseases are called orphan drugs.
ZHANG Shan, WU Chao, LIU Zhaorui, GAO Yimeng, LIU Jie, JIN Hongzhong   +5 more
doaj   +1 more source

XIAP Stabilizes DDRGK1 to Promote ER‐Phagy and Protects Against Noise‐Induced Hearing Loss

Advanced Science, EarlyView.
Mechanism of GAS‐mediated protection against noise‐induced hearing loss (NIHL). Noise exposure activates the ATF4/eIF2α axis, downregulating XIAP and promoting DDRGK1 degradation, thereby inhibiting ER‐phagy and leading to hair cell (HC) death. GAS treatment rescues XIAP and DDRGK1 expression, reactivating ER‐phagy to mitigate HC loss, synaptic damage,
Lin Yan, Yuhua Zhang, Jiawei Du, Yongjun Zhu, Wei Cao, Yongjie Wei, Han Wu, Shiyu Qiu, Shiyi Pan, Lian Chen, Pingping Liang, Renjie Chai, Jianming Yang, Qiaojun Fang   +13 more
wiley   +1 more source

The Promising Viral Threat to Bacterial Resistance: The Uncertain Patentability of Phage Therapeutics and the Necessity of Alternative Incentives [PDF]

, 2014
Bacteriophages, or “phages,” are a category of highly adept and adaptable viruses that can infect and kill bacteria. With concerns over the burgeoning antibiotic-resistance crisis looming in recent years, scientists and policymakers have expressed a ...
Todd, Kelly
core   +1 more source

Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis

BMC Medical Ethics, 2020
Background Approximately 7% of the general population is affected by an orphan disease, which, in the United States, is defined as affecting fewer than 1 in 1500 people. Disease awareness is often low and time-to-diagnosis delayed. Different legislations
Konstantin Mechler, Juliane Rausch, William K. Mountford, Markus Ries   +3 more
doaj   +1 more source

Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis

Advanced Science, EarlyView.
Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang, Mengqing Sun, Heng Dong, Xiaoting Zhang, Jingbo Zhang, Zhengguo Zhang, Mengjie Ni, Lina Li, Yunxin Pei, Xiaoyu Chen, Qian Li, Fangtian Bu, Jiacheng Huang, Liangyu Jiang, Zhuting Fang, Xuliang Chen, Jianxiang Chen, Yiting Qiao, Tian Xie   +18 more
wiley   +1 more source

Current Problems in Provision of Orphan Drugs and Ways to Solve Them

Вопросы современной педиатрии, 2016
Despite the fact that orphan (rare) diseases are characterized by a very low prevalence rate, a considerable number of people worldwide suffer from these diseases.
Alexei S. Kolbin, Roman A. Gapeshin, Stanislav M. Malyshev   +2 more
doaj   +1 more source